0:03
Hello everyone. I'm Richard Conway from Dublin, Ireland, reporting for RheumNow from ACR 2026.
0:08
And I'm here to talk to you today about an interesting poster from Sunday's poster session.
0:17
This was abstract number 0490. This was by Kuz Edal from France.
0:23
I'm probably pronouncing that name wrong, so my apologies. My French is terrible.
0:29
The full title of this is the impact of disease activity on pulmonary outcomes in a prospective cohort — I'm calling it the bad and maybe not so bad as we thought of disease activity.
0:46
And this is an interesting study because it challenges something which has been a belief of mine, which is that disease activity is a bad
0:55
thing in RA-ILD in every way — that it makes disease more likely to happen, that it makes it worse, both in terms of progression
1:04
and in terms of outcomes, if that disease activity is ongoing in a patient with RA-ILD.
1:11
So this is a relatively large study and a relatively long study.
1:17
Overall in this cohort — this prospective cohort — they have 279 patients, 258 of those were included in this analysis.
1:24
They follow out to a median of four years.
1:29
And what they were looking at essentially is disease activity in different ways, but the easiest way to understand it was in comparing moderate-high disease activity to the rest of the patients, or those in low disease activity and in remission. They measured that by DAS28-CRP.
1:47
First, in terms of looking at outcomes, having moderate to high disease activity was associated with quite a significant increase in the risk of death or the need for lung transplantation — so both relatively bad things, I would argue.
2:03
And this held up in multivariable models with a multivariable hazard ratio of 2.28.
2:09
So definitely there is a reason for us to think that controlling disease activity is good.
2:15
They looked at ILD progression then, and that's when things got a bit more surprising.
2:19
So they found progression in 50% of patients, which I mean, that's giving us good power — it's a good number of patients who are progressing here.
2:29
And they found no significant association between DAS28-CRP and disease progression.
2:34
And they looked at that in a variety of ways and still there really didn't seem to be any evidence of that.
2:43
So to me that really challenges my own thoughts about disease activity in RA-ILD, and that patients and their progression is not inherently linked to the disease activity.
2:58
And I'm not really sure how to explain that, or even more so how to explain that and tie that in with the other outcome of seeing more death and lung transplants in those patients.
3:12
One thing we should think about is that not all patients progress irrespective of disease activity.
3:19
So there can be a group of patients who are just kind of static in terms of ILD but are not progressing, whether or not they are quite active in terms of disease activity.
3:29
And I think it's equally true that there's another group of patients who have very well-controlled articular disease but whose lungs are progressing.
3:43
And I'm not so sure it's right to say that those patients do not have active disease.
3:49
My own conceptualization of a lot of those patients is that they do have active rheumatoid disease — they just don't have it in their joints.
3:59
That pulmonary process is still an active inflammatory process, often typified by ground glass infiltrates and inflammatory change on the CT.
4:10
And I think maybe our conceptualization of rheumatoid arthritis or rheumatoid disease is too joint-based at times, and we shouldn't dismiss this ongoing lung disease as a potential indicator of overall activity.
4:31
And then there's also the issue of those patients with fibrotic disease with a more clinical picture more similar to IPF, who seem to be almost similar to what we see in IPF — that the fibrosis itself could be causing progression of the fibrosis.
4:49
So there comes a tipping point with that where it's no longer disease activity but it's the fibrotic response of the body which is then generating progression.
5:01
So I think lots of potential explanations here.
5:05
I think it does challenge my own thoughts.
5:06
I'm not so sure I dismiss these patients as being inactive in terms of overall rheumatoid activity.
5:17
However, follow me on Twitter at Richard Pa Conway for more content from ACR 2026, and check out all the best ACR 2026 content at RheumNow.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.